Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression

It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) should be selected for patients with advanced non–small‐cell lung cancer (NSCLC) exhibiting high PD‐L1 expression (tumor proportion score ≥ 50%). We performed a retrospective, multicente...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2022-06, Vol.113 (6), p.2109-2117
Main Authors: Ikezawa, Yasuyuki, Mizugaki, Hidenori, Morita, Ryo, Tateishi, Kazunari, Yokoo, Keiki, Sumi, Toshiyuki, Kikuchi, Hajime, Kitamura, Yasuo, Nakamura, Atsushi, Kobayashi, Maki, Aso, Mari, Kimura, Nozomu, Yoshiike, Fumiaki, Furuta, Megumi, Tanaka, Hisashi, Sekikawa, Motoki, Hachiya, Tsutomu, Nakamura, Keiichi, Shimokawa, Mototsugu, Oizumi, Satoshi
Format: Article
Language:English
Subjects:
Age
Apoptosis
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical medicine
combination chemotherapy
Health aspects
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Medical records
Medical research
Medicine, Experimental
Non-small cell lung carcinoma
non–small‐cell lung cancer
Oncology
Original
ORIGINAL ARTICLES
Patients
PD-L1 protein
PD‐L1 inhibitor
Pembrolizumab
Pemetrexed
retrospective study
Statistical analysis
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) should be selected for patients with advanced non–small‐cell lung cancer (NSCLC) exhibiting high PD‐L1 expression (tumor proportion score ≥ 50%). We performed a retrospective, multicenter study of 300 patients with NSCLC exhibiting high PD‐L1 expression who received MONO or COMB as first‐line treatment between December 2018 and January 2020. We reviewed the medical records of all consecutive patients with no driver mutations, and assessed the patient characteristics, therapeutic regimens, treatment periods, and adverse events. In total, 166 (55%; median age: 74 years) and 134 (45%; median age: 68 years) patients received MONO and COMB, respectively. Patients were younger and had better performance status (0–1) in the COMB group (p 
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.15361